Pulse Biosciences, Inc. (PLSE), a novel bioelectric medicine company, Tuesday announced the appointment of Jon Skinner as Chief Financial Officer, with effect from February 3.
Shares of Pulse Biosciences are increasing by 6% in the pre-market trading.
Skinner most recently served as Vice President, FP&A and Investor Relations at Copeland
In the pre-market trading, Pulse Biosciences is 5.20% higher at $21.45 on the Nasdaq.
For comments and feedback: editorial@rttnews.com